INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

NTLAIntellia Therapeutics, Inc.

CIK 0001652130

EDGAR filingsOpen in network
Disclosed transactions4
Buys / sells1 / 1
Max Insider Score27
Connections4with evidence

NTLA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
20
ARK Investment Management LLC13F filer
NTLAIntellia Therapeutics, Inc.
ADD
BUY$40.04M
2.37M sh
Not disclosedAug 14, 2026quarterlySEC 13F

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Nov 4, 2026
  • ← Holdsevidence
    ARK Investment Management LLC1.9% of reported portfolio · Aug 14, 2026
  • ← Insider ofevidence
    Dube Michael PVP, Chief Accounting Officer · Jul 6, 2026
  • ← Insider ofevidence
    Goodman JesseDirector · Jun 10, 2026
27
DP
Dube Michael PVP, Chief Accounting Officer
NTLAIntellia Therapeutics, Inc.
Open-market sale
SELL
$44K
2,641 sh
Jul 1, 2026
Jul 6, 2026
traded Jul 1, 2026
+5d
SEC FORM 4

Evidence

9
GJ
Goodman JesseDirector
NTLAIntellia Therapeutics, Inc.
Grant or award
A—
13.3K sh
Jun 9, 2026Jun 10, 2026
traded Jun 9, 2026
+1dSEC FORM 4

Evidence

17
GJ
Goodman JesseDirector
NTLAIntellia Therapeutics, Inc.
Grant or award
A—
9,200 sh
Jun 9, 2026Jun 10, 2026
traded Jun 9, 2026
+1dSEC FORM 4

Evidence